• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Altria Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    7/23/25 4:50:14 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    mo-20250723
    false000076418000007641802025-07-232025-07-230000764180mo:CommonStock0.3313ParValueMember2025-07-232025-07-230000764180mo:CommonStock2.200NotesDue2027Member2025-07-232025-07-230000764180mo:CommonStock3.125NotesDue2031Member2025-07-232025-07-23

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     ____________________________________________________________________________________________________________
    FORM 8-K
    ________________________________________________________________________________________________________________
     CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): July 23, 2025
    ________________________________________________________________________________________________________________
    ALTRIA GROUP, INC.
    (Exact name of registrant as specified in its charter)
    ______________________________________________________________________________________________________________
    Virginia  1-08940  13-3260245
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)  (I.R.S. Employer
    Identification No.)
    6601 West Broad Street,Richmond,Virginia23230
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (804) 274-2200
    _______________________________________________________________________________________________________________
    (Former name or former address, if changed since last report.)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
                   Title of each class               
    Trading SymbolsName of each exchange on which registered
    Common Stock, $0.33 1/3 par value
    MONew York Stock Exchange
    2.200% Notes due 2027
    MO27New York Stock Exchange
    3.125% Notes due 2031
    MO31New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 1.01.    Entry into a Material Definitive Agreement.

    Effective July 23, 2025, Altria Group, Inc. (“Altria”) entered into an extension agreement (the “Extension Agreement”) to amend its $3.0 billion senior unsecured 5-year revolving credit agreement, dated as of October 24, 2023 (the “Credit Agreement”), with JPMorgan Chase Bank, N.A. and Citibank, N.A., as administrative agents, and the lenders named therein (the “Lenders”). The Extension Agreement extends the expiration date of the Credit Agreement from October 24, 2028 to October 24, 2029.

    All other terms and conditions of the Credit Agreement remain in full force and effect.

    Some of the Lenders under the Credit Agreement and their affiliates have various relationships with Altria and its subsidiaries involving the provision of financial services, including cash management, investment banking and trust services.

    The foregoing description of the Extension Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Extension Agreement, a copy of which is attached as Exhibit 10.1 and incorporated by reference in this Current Report on Form 8-K. The Credit Agreement was previously filed as Exhibit 10.1 to Altria’s Current Report on Form 8-K (File No. 1-08940) filed with the Securities and Exchange Commission on October 25, 2023.

    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits
    10.1
    Extension Agreement, effective July 23, 2025, among Altria Group, Inc., JPMorgan Chase Bank, N.A. and Citibank, N.A., as administrative agents, and the lenders named therein.
    104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).

    2



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ALTRIA GROUP, INC.
    By:/s/ W. HILDEBRANDT SURGNER, JR.
    Name:W. Hildebrandt Surgner, Jr.
    Title:Vice President, Corporate Secretary and
    Associate General Counsel
                            

    DATE:    July 23, 2025

    3
    Get the next $MO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    7/9/2025$50.00Underperform
    Jefferies
    7/2/2025$59.00Sell → Neutral
    UBS
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    More analyst ratings

    $MO
    SEC Filings

    View All

    SEC Form 8-K filed by Altria Group Inc.

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    8/6/25 4:57:40 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form FWP filed by Altria Group Inc.

    FWP - ALTRIA GROUP, INC. (0000764180) (Subject)

    8/4/25 4:58:18 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Altria Group Inc.

    10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

    7/30/25 7:22:57 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altria Reports 2025 Second-Quarter and First-Half Results; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 second-quarter and first-half business results and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses," said Billy Gifford, Altria's Chief Executive Officer. "In oral tobacco, on! delivered strong performance and was the substantial driver of the segment's growth in the quarter. And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases." "We are raising the lower-end of ou

    7/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast of 2025 Second-Quarter and First-Half Results

    Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 second-quarter and first-half business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com. During the webcast, Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Chief Financial Officer, will discuss the Company's 2025 second-quarter and first-half business results and answer questions from the investment community and news media. The webcast will be in a listen-only mode. Pre-event registration is neces

    7/16/25 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

    5/15/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:08:44 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:03:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    New insider Patterson Katie F claimed ownership of 17,191 shares (SEC Form 3)

    3 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    8/1/25 2:37:57 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Yzaguirre Mario Max was granted 3,219 shares, increasing direct ownership by 25% to 16,252 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:06:43 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Strahlman Ellen R was granted 3,219 shares, increasing direct ownership by 16% to 23,087 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:05:17 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Altria with a new price target

    Jefferies resumed coverage of Altria with a rating of Underperform and set a new price target of $50.00

    7/9/25 8:26:04 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

    7/2/25 7:43:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria downgraded by Deutsche Bank

    Deutsche Bank downgraded Altria from Buy to Hold

    4/1/25 3:04:54 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    View All

    Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

    Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

    2/26/24 4:30:00 PM ET
    $ARIS
    $MO
    $PXD
    Oilfield Services/Equipment
    Energy
    Medicinal Chemicals and Botanical Products
    Health Care

    Seasoned Financial Expert Max Yzaguirre Named Strategic Advisor of FireFly Automatix, Leader in AV and EV-Driven Professional Turfgrass Mowing Technology

    -Yzaguirre joins a list of seasoned professionals on FireFly's team with specific expertise in initiating and growing businesses in evolving market conditions- FireFly Automatix, Inc., the de facto industry leader in AV and EV professional turfgrass mowing technology, today announced the appointment of financial and leadership expert M. Max Yzaguirre as a strategic advisor to CEO Andrew Limpert and the board of directors. Yzaguirre's appointment follows the recent additions of former WPP Group CFO Paul Richardson and capital markets professional Liz Hocker to FireFly's board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202401

    1/23/24 9:00:00 AM ET
    $ARIS
    $LBC
    $MO
    Oilfield Services/Equipment
    Energy
    Major Banks
    Finance

    Altria Group, Inc. Announces Retirement of Director Nabil Y. Sakkab From Board of Directors

    Nabil Y. Sakkab, a director of Altria Group, Inc. ("Altria") since 2008, will retire from service on our Board of Directors following the completion of his current term. Consequently, Mr. Sakkab will not stand for re-election to the Board of Directors at Altria's 2024 Annual Meeting of Shareholders, which Altria anticipates holding on May 16, 2024. "Nabil's contributions have significantly benefited Altria over the past 15 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank him for his long and distinguished service and wish him the very best upon his retirement." Dr. Sakkab is Chair of the Innovation Committee and is a member of the Executive, Finance, and

    10/25/23 4:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/24 4:58:48 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/23 2:49:28 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/9/23 10:54:46 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Financials

    Live finance-specific insights

    View All

    Altria Reports 2025 Second-Quarter and First-Half Results; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 second-quarter and first-half business results and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses," said Billy Gifford, Altria's Chief Executive Officer. "In oral tobacco, on! delivered strong performance and was the substantial driver of the segment's growth in the quarter. And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases." "We are raising the lower-end of ou

    7/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

    5/15/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

    4/29/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care